Glidepath Health Launches to Bring Operational Certainty to Cell and Gene Therapy Delivery

Glidepath Health emerged from stealth with an AI-driven platform that orchestrates cell and gene therapy logistics across apheresis scheduling, manufacturing slots, cryogenic shipping, and infusion, with initial deployments planned this year. The startup holds an exclusive license from Memorial Sloan Kettering Cancer Center covering the ImmunoChain clinical supply chain technology developed there; financial terms were not disclosed. AlleyCorp and A-Squared Ventures back the company, with principals from both firms on its board.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.